Healthcare Services

Major Depressive Disorder Market Overview (2026–2030) With Industry Insights

April 23, 2026April 26, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Large Will The Major Depressive Disorder Market Be By 2030 Compared To Its 2026 Market Size?

The major depressive disorder market has experienced consistent expansion in recent years. This market is projected to grow from $6.26 billion in 2025 to $6.44 billion in 2026, achieving a compound annual growth rate (CAGR) of 2.9%. Historically, this growth can be attributed to the increasing prevalence of depressive disorders, growing societal awareness of mental health issues, wider availability of antidepressant medications, the expansion of psychiatric care infrastructure, and improved diagnostic guidelines for mood disorders.

The major depressive disorder market is projected to experience consistent expansion over the upcoming years, with its size anticipated to reach $7.49 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 3.9%. This growth during the forecast period is attributable to an escalating mental health burden resulting from lifestyle stress, the increasing uptake of digital mental health platforms, a rising demand for personalized depression treatments, broader insurance coverage for mental health care, and sustained innovation in neuromodulation therapies. Noteworthy trends in the forecast timeframe include the growing adoption of combination therapy approaches, an increasing preference for non-invasive brain stimulation treatments, enhanced awareness and diagnosis of depression, the expansion of telepsychiatry and remote mental health care, and greater acceptance of novel and rapid-acting antidepressants.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13042&type=smp

What Primary Drivers Are Shaping The Major Depressive Disorder Market?

The increasing prevalence of substance and alcohol abuse is anticipated to fuel the expansion of the major depressive disorder market. Substance and alcohol abuse refers to patterns of detrimental and excessive consumption of various substances, including alcohol, which can result in adverse physical, psychological, and social repercussions. These conditions frequently co-exist with major depressive disorder, with each tending to exacerbate the other, thereby considerably elevating the likelihood of both physical and mental detriment. For example, a survey released in July 2024 by the Substance Abuse and Mental Health Services Administration, a US-based department of health and human services, reported that 3.1% of people (8.9 million) misused opioids in 2023. Additionally, 21.8% of individuals aged 12 or older utilized marijuana, establishing it as the most frequently consumed illicit drug. Furthermore, 9.4% of individuals aged 12 or older engaged in nicotine vaping in the preceding month, an increase from 8.3% recorded in 2022. Consequently, the escalating incidence of substance and alcohol abuse is propelling the growth of the major depressive disorder market.

How Are Segments Identified Within The Major Depressive Disorder Market Segment Framework?

The major depressive disorder market covered in this report is segmented –

1) By Treatment: Psychotherapy, Medications, Electroconvulsive Therapy (ECT), Transcranial Magnetic Stimulation (TMS), Other Treatments

2) By Diagnosis: Psychiatric Evaluations, Diagnostic And Statistical Manual of Mental Disorders (DSM-5)

3) By End-User: Clinics, Hospitals, Other End-Users

Subsegments:

1) By Psychotherapy: Cognitive Behavioral Therapy (CBT), Interpersonal Therapy (IPT), Dialectical Behavior Therapy (DBT), Psychodynamic Therapy

2) By Medications: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants (TCAs), Monoamine Oxidase Inhibitors (MAOIs), Atypical Antidepressants

3) By Electroconvulsive Therapy (ECT): Unilateral ECT, Bilateral ECT, Modified ECT

4) By Transcranial Magnetic Stimulation (TMS): Repetitive Transcranial Magnetic Stimulation (rTMS), Deep Transcranial Magnetic Stimulation (dTMS), Theta Burst Stimulation (TBS), Navigated Brain Stimulation (nTMS)

5) By Other Treatments: Cognitive Behavioral Therapy (CBT), Psychodynamic Therapy, Interpersonal Therapy (IPT), Vagus Nerve Stimulation (VNS), Ketamine Therapy, Bright Light Therapy, Psychedelic-Assisted Therapy, Medication (Antidepressants)

What Trends Are Affecting The Growth Of The Major Depressive Disorder Market?

Prominent companies operating within the major depressive disorder (MDD) market are concentrating their efforts on developing innovative solutions, such as prescription digital therapeutics (PDTs), to address the escalating demand for scalable access to evidence-based psychotherapy, adjunctive treatments for partial responders, and remote, measurement-driven care pathways. Prescription digital therapeutics (PDTs) are defined as software-as-medical-device interventions delivered via prescription, which integrate clinically validated therapeutic content, tools for remote engagement and adherence, and data capture capabilities for clinicians; in contrast to traditional antidepressant medications or in-person psychotherapy, PDTs offer repeatable, standardized, and remotely supervised behavioral interventions that can either complement pharmacotherapy or fill gaps in provider access where limited. For example, in April 2024, Otsuka Pharmaceutical Co., a Japan-based pharmaceutical company, collaborated with Click Therapeutics to launch Rejoyn (developed as CT-152), a prescription digital therapeutic authorized by the U.S. FDA for use as an adjunctive treatment for adults with MDD who are concurrently on antidepressant medication. Rejoyn constitutes a six-week, smartphone-delivered program structured around clinically validated cognitive-emotional brain-training exercises (specifically, the Emotional Faces Memory Task/EFMT) and brief therapeutic lessons designed to enhance the cognitive control of emotion. The application operates through prescribed delivery, where patients download and complete scheduled sessions on their smartphone, while clinicians prescribe and monitor usage, and its efficacy was examined in the MIRAI randomized, sham-controlled trial, which demonstrated symptom improvement compared to the control. Its distinctive characteristics include its neuromodulatory design, intended to target neural networks implicated in emotion processing, personalized remote reminders to boost adherence, and regulatory clearance as a medical device rather than a wellness app.

Who Are The Companies Competing Within The Major Depressive Disorder Market?

Major companies operating in the major depressive disorder market are Pfizer Inc., Janssen Research and Development LLC, Merck and Co. Inc., Novartis AG, Sanofi-Aventis US LLC, Bristol Myers Squibb Co., AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Biogen Inc., Otsuka Pharmaceuticals Co. Ltd., Forest Laboratories Inc., H. Lundbeck A/S, Richter Gedeon plc, Allergan plc, Neurocrine Biosciences Inc., BlackThorn Therapeutics Inc., Intra-Cellular Therapies Inc., Axsome Therapeutics Inc., Luye Pharma Group, BrainsWay Ltd., Neumora Therapeutics Inc., Chase Therapeutics Corporation, SAGE Therapeutics Inc., Relmada Therapeutics Inc., Fabre-Kramer Pharmaceuticals Inc., Vistagen Therapeutics Inc.

Get The Full Major Depressive Disorder Market Report:

https://www.thebusinessresearchcompany.com/report/major-depressive-disorder-global-market-report

Which Region Is The Largest In The Major Depressive Disorder Market?

North America was the largest region in the major depressive disorder market in 2025. The regions covered in the major depressive disorder market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Major Depressive Disorder Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/major-depressive-disorder-global-market-report

Browse Through More Reports Similar to the Global Major Depressive Disorder Market 2026, By The Business Research Company

E Pharmacy Market Report 2026

https://www.thebusinessresearchcompany.com/report/e-pharmacy-global-market-report

Digital Pharmacy Market Report

https://www.thebusinessresearchcompany.com/report/digital-pharmacy-global-market-report

Pharmacy Management System Market Report

https://www.thebusinessresearchcompany.com/report/pharmacy-management-system-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795